Bayer Shares Under Intense Pressure as Legal Liabilities Mount

Bayer reports €3.76B Q4 loss on legal provisions, forecasts negative free cash flow for 2026 ahead of crucial Supreme Court glyphosate ruling.

Investors in Bayer AG (BAYN) are facing a stark reality as the company's latest financial disclosures paint a picture of severe strain. The conglomerate continues to grapple with the extensive fallout from protracted litigation and operational headwinds, with its full-year 2025 results revealing billions in losses. The guidance for 2026 has done little to reassure the market, instead amplifying concerns, particularly around cash generation.

A Crucial Supreme Court Decision Looms

Beyond the immediate financial figures, a pivotal event is on the horizon. The U.S. Supreme Court is expected to rule on the glyphosate litigation complex in June 2026. Until that decision is delivered, legal uncertainty and growing competitive pressure from generics in the pharmaceuticals division are likely to be dominant themes influencing the stock's performance.

Legal Provisions Drive Deep Losses

The financial damage is most clearly illustrated in the fourth quarter of 2025. Bayer reported a net loss that ballooned to €3.76 billion, a significant deterioration from the €335 million loss recorded in the same period a year earlier. This steep decline is primarily attributable to massive provisions for ongoing legal disputes. Across the entire 2025 fiscal year, these litigation provisions totaled €7.5 billion.

The glyphosate cases in the United States remain a particularly heavy burden. A proposed settlement outlines payments of up to $7.25 billion, which would be distributed over a span of 21 years. Management is already bracing for a substantial cash impact in the current year, anticipating outflows of approximately €5 billion in 2026 to address legal matters.

Cash Flow Forecast Sparks Alarm

The company's outlook for 2026 has further dampened market sentiment. While Bayer is targeting currency-adjusted sales between €45 and €47 billion, its forecast for EBITDA before special items, projected in a range of €9.6 to €10.1 billion, fell short of many analysts' expectations.

The most worrying element for shareholders is the forecast for free cash flow. For 2026, Bayer anticipates it will be deeply negative, landing between minus €1.5 billion and minus €2.5 billion. This projection raises urgent questions about whether an ambitious €2 billion cost-saving program can be implemented swiftly enough to mitigate the financial pressure from settlement payments. These planned cuts are a necessary response to the massive cash drain.

Investor Reaction and Technical Position

Market participants have responded negatively to the weak guidance and the proposed dividend of just €0.11 per share. Following a decline of over ten percent within a single week, the stock recently traded at $11.05. With a Relative Strength Index (RSI) reading of 16.3, the shares are technically considered to be in massively oversold territory.